Covid-19: PGI Rohtak To Begin Third Phase Trial Of Covaxin On Nov 20, VC Says Over 90% Efficacy Expected

Coronavirus Covid-19 Vaccine: Bharat Biotech International Limited’s Covaxin will undergo the third phase trial in Haryana from November 20. Here is what the vice-chancellor of PGI Rohtak Dr. OP Kalra revealed about it.

(Representative Image/Getty)

New Delhi: In a promising development in the search for the Coronavirus vaccine, Rohtak's Post-Graduate Institute (PGI) will begin the third phase trial of Covaxin on November 20.  Talking to the media, the vice-chancellor of PGI Rohtak Dr. OP Kalra talked about the phase 3 trials beginning on November 20. He revealed certain details saying that 200 volunteers will be administered the vaccine early to study its anti-bodies response. There will be 2 doses of this vaccine candidate, the second dose will be given 28 days after the first dose. "Third phase trial of Covaxin to start on November 20. 200 volunteers to be administered the vaccine early to study its anti-bodies response. There'll be 2 doses, the second dose to be given 28 days after the first dose. Expecting vaccine's efficacy to be more than 90%,": VC, PGI Rohtak said. Haryana home minister Anil Vij had earlier announced that the third phase trial of Bharat Biotech International Limited’s Covaxin. He had also offered to be the first volunteer for the vaccine trial. "Trial for third phase of Covaxin a coronavirus vaccine product of Bharat Biotech to start in Haryana on 20th November. I have offered myself as the first volunteer to get vaccinated," the minister wrote on Twitter. Earlier on Wednesday, Pfizer Inc revealed the final analysis of clinical-trial data that showed that its Covid-19 vaccine was 95% effective against the disease that has gripped the world. The company is now looking to apply for the first US regulatory authorization for a coronavirus shot. US drugmaker and partner BioNTech SE reported that no safety problems have been witnessed so far in a trial that involved as many as 44,000 participants and that their vaccine can protect people of all age groups and ethnicities. Several promising developments are being reported in the vaccine candidates. Moderna Inc.’s vaccine is stated to be as effective, while the third rival from AstraZeneca Plc and the University of Oxford is also expected to release trial results in the coming days.